Korean Red Ginseng and Metabolic Syndrome
キーワード
概要
説明
The details of study objective are followed by these:
- comparison of blood pressure before and after Korean red ginseng administration
- comparison of metabolic indicator before and after Korean red ginseng administration
- comparison of oxidative stress and inflammatory markers before and after Korean red ginseng administration
- comparison of arterial stiffness before and after Korean red ginseng administration
日付
最終確認済み: | 01/31/2012 |
最初に提出された: | 09/10/2009 |
提出された推定登録数: | 09/10/2009 |
最初の投稿: | 09/13/2009 |
最終更新が送信されました: | 02/22/2012 |
最終更新日: | 02/26/2012 |
最初に提出された結果の日付: | 01/18/2012 |
最初に提出されたQC結果の日付: | 01/18/2012 |
最初に投稿された結果の日付: | 02/23/2012 |
実際の研究開始日: | 07/31/2009 |
一次完了予定日: | 12/31/2010 |
研究完了予定日: | 12/31/2010 |
状態または病気
介入/治療
Dietary Supplement: Korea red ginseng
Dietary Supplement: starch capsule
段階
アームグループ
腕 | 介入/治療 |
---|---|
Placebo Comparator: starch capsule | Dietary Supplement: starch capsule 5 capsules three times everyday for 12 weeks |
Experimental: Korea red ginseng | Dietary Supplement: Korea red ginseng 5 capsules (300 mg/capsule) three times everyday for 12 weeks |
適格基準
研究の対象となる年齢 | 20 Years に 20 Years |
研究に適格な性別 | All |
健康なボランティアを受け入れる | はい |
基準 | Inclusion Criteria:(three or more of following five factors) - waist circumference(male: more than 90cm, female: more than 80cm) - blood pressure(systolic: more than 130mmHg, diastolic: more than 85mmHg) - fasting plasma glucose: more than 100mg/dL - fasting triglycerides: more than 150mg/dL - High-density lipoprotein(HDL)-cholesterol(male: less than 40mg/dL, female: less than 50mg/dL) Exclusion Criteria: (any one of following factors) - uncontrolled blood pressure(systolic: more than 160mmHg, diastolic: more than 100mmHg) or subjects taking blood pressure lowering drug - Type 2 diabetes patients or fasting plasma glucose more than 126mg/dL - triglyceride more than 400mg/dL, total cholesterol more than 250mg/dL - subjects taking antilipidemic drug - past history of coronary heart disease or cerebrovascular disease |
結果
主な結果の測定
1. Change in the Pre- and Post-treatment Systolic Blood Pressure [baseline and 12 weeks]
二次的な結果の測定
1. Change in the Pre- and Post-treatment Oxidized Low-densty Lipoprotein(LDL) [baseline and 12 weeks]